Visilizumab

From Wikipedia, the free encyclopedia

Visilizumab^?
Therapeutic monoclonal antibody
Source	Human
Target	CD3 receptor
Identifiers
CAS number	?
ATC code	?
PubChem	?
Chemical data
Formula	?
Mol. mass	?
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	?

Visilizumab (tentative trade name Nuvion, PDL BioPharma Inc.) is a humanized monoclonal antibody. It is being investigated for use as an immunosuppressive drug in patients with ulcerative colitis and Crohn's disease. Visilizumab binds to the CD3 receptor on certain activated T cells without effecting resting T cells. It is currently under clinical studies for the treatment of ulcerative colitis and Crohn's disease. ^[1]

[edit] References

^ "PDL BioPharma, Development Pipeline - Nuvion (visilizumab)". Retrieved on 2008-02-11.

v • d • e

Immunomodulators – Immunosuppressants – Immunosuppressive drugs (L04)

Intracellular
(signal initiation)

Antimetabolites	purine synthesis inhibitor: Azathioprine · Mycophenolic acid pyrimidine synthesis inhibitor: Leflunomide · Teriflunomide antifolate: Methotrexate

Macrolides/ other IL-2 inhibitors	FKBP/Cyclophilin/Calcineurin: Tacrolimus · Ciclosporin · Pimecrolimus Abetimus · Gusperimus

TNF-α inhibitor	Thalidomide

Intracellular
(signal reception)

IL-1 receptor antagonists	Anakinra

mTOR	Sirolimus · Deforolimus · Everolimus · Temsirolimus · Zotarolimus

Extracellular

Antibodies

Monoclonal

Serum target (noncellular)	Complement component 5 (Eculizumab) · TNFs (Infliximab, Adalimumab, Certolizumab pegol, Afelimomab, Golimumab) · Interleukin 5 (Mepolizumab) · Immunoglobulin E (Omalizumab) · BAYX (Nerelimomab) Interferon (Faralimomab) IL-6 (Elsilimomab) IL-12 and IL-13 (Ustekinumab)

Cellular target	CD3 (Muromonab-CD3, Otelixizumab, Teplizumab, Visilizumab) · CD4 (Clenoliximab, Keliximab, Zanolimumab) · CD11a (Efalizumab) · CD18 (Erlizumab) · CD20 (Afutuzumab, Ocrelizumab, Pascolizumab) · CD23 (Lumiliximab) · CD40 (Teneliximab, Toralizumab) · CD62L/L-selectin (Aselizumab) · CD80 (Galiximab) · CD147/Basigin (Gavilimomab, Ziralimumab) · CD154 (Ruplizumab) BLyS (Belimumab) · CTLA-4 (Ipilimumab, Tremelimumab) · CAT (Bertilimumab, Lerdelimumab, Metelimumab) · Integrin (Natalizumab) · Interleukin-6 receptor (Tocilizumab) · LFA-1 (Odulimomab) IL-2 receptor/CD25 (Basiliximab, Daclizumab, Inolimomab) T-lymphocyte (Zolimomab aritox)

Unsorted	Atlizumab, Atorolimumab, Cedelizumab, Dorlimomab aritox, Dorlixizumab, Fontolizumab, Gantenerumab, Gomiliximab, Lebrilizumab, Maslimomab, Morolimumab, Pexelizumab, Reslizumab, Rovelizumab, Siplizumab, Talizumab, Telimomab aritox, Vapaliximab, Vepalimomab

Polyclonal

Anti-thymocyte globulin · Anti-lymphocyte globulin

-cept (Fusion protein)

CTLA-4 (Abatacept, Belatacept) · Aflibercept · Alefacept · Rilonacept · TNF inhibitor (Etanercept)

v • d • e Humanized monoclonal antibodies ("-zu-")

"-tuzu-" (tumor)	Afutuzumab, Alemtuzumab, Bevacizumab/Ranibizumab, Bivatuzumab mertansine, Cantuzumab mertansine, Citatuzumab bogatox, Dacetuzumab, Elotuzumab^†, Etaracizumab, Farletuzumab, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Labetuzumab, Lintuzumab, Matuzumab^†, Milatuzumab, Nimotuzumab, Pertuzumab, Sibrotuzumab, Sontuzumab, Tacatuzumab tetraxetan, Tigatuzumab, Trastuzumab, Tucotuzumab celmoleukin, Veltuzumab

"-lizu-" (immune system)	immunosuppressive: Aselizumab, Atlizumab, Apolizumab, Cedelizumab, Certolizumab pegol, Daclizumab, Eculizumab, Efalizumab, Epratuzumab, Erlizumab, Fontolizumab, Lebrilizumab, Mepolizumab, Natalizumab, Ocrelizumab, Omalizumab, Pascolizumab, Pexelizumab, Reslizumab, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Teplizumab, Tocilizumab, Toralizumab, Vedolizumab, Visilizumab, TGN1412 non-immunosuppressive: Ibalizumab^†

"-bazu-" (bacterial)	Tefibazumab^†

"-cizu-" (cardiovascular)	Alacizumab pegol, Bevacizumab, Sonepcizumab, Tadocizumab

"-nezu-"/"-neuzu-" (nervous system)	Bapineuzumab, Tanezumab

"-toxazu-" (toxin as target)	Urtoxazumab

"-vizu-" (viral infections)	Felvizumab, Motavizumab, Palivizumab, PRO 140^†

"-kinzu-" (interleukin as target)	Anrukinzumab

^†Undergoing clinical trials.

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "http://en.wikipedia.org/wiki/Visilizumab"

Categories: Monoclonal antibodies | Monoclonal antibody stubs

Visilizumab

From Wikipedia, the free encyclopedia

[edit] References

WANT TO ADVERTISE ON ALL OF OVER 11 MILLION SUBPAGES WE HAVE ON THIS SITE FOR UNDER $15? CLICK HERE!